X-Chem, Pfizer team up on orphan drug development
- Pfizer is teaming with the biotech company, X-Chem, to discover small molecules that can be developed for the treatment of inflammatory and orphan diseases.
- X-Chem is privately held and has a proprietary drug-discovery engine that Pfizer considers innovative.
- The companies have agreed that Pfizer has an exclusive option to license any drugs that are generated as part of this collaboration. Financial terms have not been disclosed.
As a privately held biotech company, X-Chem brings drug-discovery technology to its collaborative partnership with Pfizer. As part of this collaboration, X-Chem will “leverage a high-diversity, proprietary DNA-encoded, small-molecule library to seek that identification of novel leads for Pfizer’s programs," according to a new release announcing the agreement. X-Chem also has noteworthy informatics capabilities and screening expertise.
The overall goal is to continue to expand Pfizer’s pipeline.
- Pharmaceutical Business Review X-Chem, Pfizer to develop new treatments for inflammatory, orphan diseases